diff --git a/Latex/Paper/sections/01_introduction.tex b/Latex/Paper/sections/01_introduction.tex
index 6375efd..f72b0a9 100644
--- a/Latex/Paper/sections/01_introduction.tex
+++ b/Latex/Paper/sections/01_introduction.tex
@@ -78,7 +78,7 @@ The author states in his conclusion:
 
 From this we see that there was a cascade of issues leading to the failure to 
 develop this novel drug. 
-Knowing how to separate 
+
 
 
 
diff --git a/Latex/Paper/sections/05_LitReview.tex b/Latex/Paper/sections/05_LitReview.tex
index 97ea175..066dd7d 100644
--- a/Latex/Paper/sections/05_LitReview.tex
+++ b/Latex/Paper/sections/05_LitReview.tex
@@ -147,6 +147,9 @@ This may be an operational change to reduce the cost of new drugs.
 
 \cite{dimasi_ValueImproving_2002}
 used data on 68 investigational drugs from 10 firms to simulate how reducing
-time in development adds to the 
+time in development reduces the costs of developing drugs. 
+He estimates that reducing Phase III of clinical trials by one year would 
+reduce total costs by about 8.9\% and that moving 5\% of clinical trial failures
+from phase III to Phase II would reduce out of pocket costs by 5.6\%. 
 
 \end{document}